Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine

International Journal of Infectious Diseases

Volumn 33, Issue , 2015, Pages 22-27

  Payeras, Antoni ^a   Villoslada, Aroa ^a   Garau, Margarita ^a   Salvador, M Neus ^a   Gallegos, M Carmen ^a  

^a HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Clinical features; Outcome; Pneumococcal conjugate vaccines; Pneumococcal invasive disease; Pneumococcal pneumonia

Indexed keywords

AMOXICILLIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMONIA; PROSPECTIVE STUDY; SEROTYPE; VACCINATION; CHILD; CLASSIFICATION; DRUG EFFECTS; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; VACCINATION; YOUNG ADULT;

EID: 84921731919     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.12.035     Document Type: Article

References (40)

1. Musher D.M. Streptococcus pneumoniae. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, 2623-2642. Churchill Livingstone, Elsevier, Philadelphia. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
2. Pneumococcal disease. Epidemiology and prevention of vaccine-preventable diseases 2011, 233-248. Centers for Disease Control Prevention, Public Health Foundation, Washington, DC. 12th ed. W. Atkinson, S. Wolfe, J. Hamborsky (Eds.).
3. World Health Organization 23-Valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008, 83:373-384.
4. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
5. Albrich W.C., Baughman W., Schmotzer B., Farley M.M. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007, 44:1569-1576.
6. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction in eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57:144-148. Centers for Disease Control, Prevention.
7. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the 14 Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009, 49:205-212.
8. Shafinoori S., Ginocchio C.C., Greenberg A.J., Yeoman E., Cheddie M., Rubin L.G. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr Infect Dis J 2005, 24:10-16.
9. Singleton R.J., Hennessy T.W., Bulkow L.R., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297:1784-1792.
10. Jacobs M.R., Good C.E., Bajaksouzian S., Windau A.R. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008, 47:1388-1395.
11. Lepoutre A., Varon E., Georges S., Gutmann L., Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2008, 13:18962.
12. Calbo E., Díaz A., Cañadell E., et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 2006, 12:867-872.
13. Muñoz-Almagro C., Jordan I., Gene A., Latorre C., García-García J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46:174-182.
14. Picazo J., Ruiz Contreras J., Casado J. Universal vaccination with PCV7 vs. VNC13: changes in invasive pneumococcal disease incidence rates by clinical presentation and children age. 31st Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2013) 2013.
15. Picazo J., Ruiz-Contreras J., Casado-Flores J., et al. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid (2007-2011). Pediatr Infect Dis J 2013, 32:656-661.
16. Picazo J., Ruiz-Contreras J., Hernandez B., et al. Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid. Vaccine 2011, 29:1770-1776.
17. Picazo J., Ruiz Contreras J., Casado J. Changes in incidence of serotype-specific clinical presentations of invasive pneumococcal disease following switch from PCV7 to VNC13 for universal vaccination. 31st Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2013) 2013.
18. Moore M., Link-Gelles R., Farley M., et al. Early impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old, U.S, 2010. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2011.
19. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
20. Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975, 50:339-344.
21. American Thoracic Society (ATS) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
22. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100-S20. Wayne, PA: CLSI; 2010.
24. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:816-819. Centers for Disease Control, Prevention.
25. Picazo J., González-Romo F., García Rojas A., et al. Consenso sobre la vacunación antineumocócica en el adulto con patología de base. Rev Esp Quimioter 2013, 26:232-252.
26. Schenkein J.G., Nahm M.H., Dransfield M.T. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 2008, 133:767-774.
27. Pedersen R.H., Lohse N., Østergaard L., Søgaard O.S. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011, 12:323-333.
28. Pitsiou G.G., Kioumis I.P. Pneumococcal vaccination in adults: does it really work?. Respir Med 2011, 105:1776-1783.
29. Jackson L.A., Gurtman A., van Cleeff M., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013, 31:3577-3584.
30. Hausdorff W.P. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 2007, 25:2406-2412.
31. Grivea I.N., Tsantouli A.G., Chryssanthopoulou D.C., Syrogiannopoulos G.A. Interaction of the heptavalent pneumococcal conjugate vaccine and the use of individual antibiotics among children on nasopharyngeal colonization with erythromycin-resistant Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2010, 29:97-105.
32. Kyaw M.H., Lynfield R., Schaffner W., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455-1463.
33. Mera R.M., Miller L.A., White A. Antibacterial use and Streptococcus pneumoniae penicillin resistance: a temporal relationship model. Microb Drug Resist 2006, 12:158-163.
34. Farrell D.J., Klugman K.P., Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007, 26:123-128.
35. Ardanuy C., Marimon J.M., Calatayud L., et al. Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies. PLoS One 2012, 7:e43619.
36. Liñares J., Ardanuy C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010, 16:402-410.
37. Pilishvili T., Lexau C., Farley M.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
38. Karnezis T.T., Smith A., Whittier S., Haddad J., Saiman L. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS One 2009, 4:e5965.
39. Secretaria General de Sanidad. Dirección General de Salud Pública. Ministerio de Salud y Consumo. Gobierno de España. Enfermedad invasiva por Streptococcus pneumoniae: implicación de la vacunación con la vacuna conjugada heptavalente (Abril 2006). Available at: https://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/neumo.pdf, 2006. Accessed date: December 2015.
40. Navarro-Torne A., Gomes-Dias J., Quinten C.H., et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the postheptavalent conjugate vaccine era. Vaccine 2014, 32:3644-3650.